| Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer CL Vogel, MA Cobleigh, D Tripathy, JC Gutheil, LN Harris, ... Journal of clinical oncology 20 (3), 719-726, 2002 | 4166 | 2002 |
| Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed … MA Cobleigh, CL Vogel, D Tripathy, NJ Robert, S Scholl, L Fehrenbacher, ... Journal of clinical Oncology 17 (9), 2639-2639, 1999 | 3677 | 1999 |
| Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing … MD Pegram, A Lipton, DF Hayes, BL Weber, JM Baselga, D Tripathy, ... Journal of clinical oncology 16 (8), 2659-2671, 1998 | 1474 | 1998 |
| Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial D Tripathy, SA Im, M Colleoni, F Franke, A Bardia, N Harbeck, SA Hurvitz, ... The lancet oncology 19 (7), 904-915, 2018 | 903 | 2018 |
| Overall survival with ribociclib plus endocrine therapy in breast cancer SA Im, YS Lu, A Bardia, N Harbeck, M Colleoni, F Franke, L Chow, J Sohn, ... New England journal of medicine 381 (4), 307-316, 2019 | 902 | 2019 |
| Clinical practice guidelines on the evidence‐based use of integrative therapies during and after breast cancer treatment H Greenlee, MJ DuPont‐Reyes, LG Balneaves, LE Carlson, MR Cohen, ... CA: a cancer journal for clinicians 67 (3), 194-232, 2017 | 756 | 2017 |
| Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications C Osborne, P Wilson, D Tripathy The oncologist 9 (4), 361-377, 2004 | 492 | 2004 |
| Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III … JJ Body, IJ Diel, M Lichinitzer, A Lazarev, M Pecherstorfer, R Bell, ... British journal of cancer 90 (6), 1133-1137, 2004 | 419 | 2004 |
| Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER AM Brufsky, M Mayer, HS Rugo, PA Kaufman, E Tan-Chiu, D Tripathy, ... Clinical Cancer Research 17 (14), 4834-4843, 2011 | 416 | 2011 |
| Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) LJ Esserman, DA Berry, MCU Cheang, C Yau, CM Perou, L Carey, ... Breast cancer research and treatment 132, 1049-1062, 2012 | 373 | 2012 |
| Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer H Greenlee, LG Balneaves, LE Carlson, M Cohen, G Deng, D Hershman, ... Journal of the National Cancer Institute Monographs 2014 (50), 346-358, 2014 | 363 | 2014 |
| Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression D Tripathy, DJ Slamon, M Cobleigh, A Arnold, M Saleh, JE Mortimer, ... Journal of Clinical Oncology 22 (6), 1063-1070, 2004 | 356 | 2004 |
| Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management C Miaskowski, M Dodd, C West, K Schumacher, SM Paul, D Tripathy, ... Journal of Clinical Oncology 22 (9), 1713-1720, 2004 | 314 | 2004 |
| Effects of aerobic and resistance exercise on metabolic syndrome, sarcopenic obesity, and circulating biomarkers in overweight or obese survivors of breast cancer: a randomized … CM Dieli-Conwright, KS Courneya, W Demark-Wahnefried, N Sami, K Lee, ... Journal of Clinical Oncology 36 (9), 875, 2018 | 300 | 2018 |
| Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial CM Dieli-Conwright, KS Courneya, W Demark-Wahnefried, N Sami, K Lee, ... Breast Cancer Research 20, 1-10, 2018 | 299 | 2018 |
| First-line Herceptin® monotherapy in metastatic breast cancer CL Vogel, MA Cobleigh, D Tripathy, JC Gutheil, LN Harris, ... Oncology 61 (Suppl. 2), 37-42, 2001 | 293 | 2001 |
| Lack of adherence with the analgesic regimen: a significant barrier to effective cancer pain management C Miaskowski, MJ Dodd, C West, SM Paul, D Tripathy, P Koo, ... Journal of clinical oncology 19 (23), 4275-4279, 2001 | 288 | 2001 |
| Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival MJM Magbanua, LB Swigart, HT Wu, GL Hirst, C Yau, DM Wolf, A Tin, ... Annals of Oncology 32 (2), 229-239, 2021 | 273 | 2021 |
| CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers S Vijayaraghavan, C Karakas, I Doostan, X Chen, T Bui, M Yi, ... Nature communications 8 (1), 15916, 2017 | 263 | 2017 |
| First-line, single-agent Herceptin®(trastuzumab) in metastatic breast cancer: a preliminary report C Vogel, MA Cobleigh, D Tripathy, JC Gutheil, LN Harris, L Fehrenbacher, ... European journal of cancer 37, 25-29, 2001 | 251 | 2001 |
